Publications by authors named "Daniela Toneatto"

Claim this Profile
B
Breadth of immune response, immunogenicity, reactogenicity, and safety for a pentavalent meningococcal ABCWY vaccine in healthy adolescents and young adults: results from a phase 3, randomised, controlled observer-blinded trial.
Terry Nolan, Chiranjiwi Bhusal, Jiří Beran, Mark Bloch, Benhur Sirvan Cetin, Daniela Toneatto

Lancet Infect Dis· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity, Reactogenicity, and Safety of a Pentavalent Meningococcal ABCWY Vaccine in Adolescents and Young Adults Who Had Previously Received a Meningococcal ACWY Vaccine: A Phase 3, Randomized Controlled Clinical Study.
Terry Nolan, Chiranjiwi Bhusal, Alejandro Hoberman, Conrado J Llapur, Olga Voloshyna, Daniela Toneatto

Clin Infect Dis· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methods to evaluate the performance of a multicomponent meningococcal serogroup B vaccine.
Ray Borrow, Laura Tomasi Cont, Daniela Toneatto, Stefania Bambini, Shravani Bobde

mSphere· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4CMenB journey to the 10-year anniversary and beyond.
Véronique Abitbol, Federico Martinón-Torres, Muhamed-Kheir Taha, Terry Nolan, Alessandro Muzzi, Daniela Toneatto

Hum Vaccin Immunother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults.
Terry Nolan, Chiranjiwi Bhusal, Jiří Beran, Mark Bloch, Benhur S Cetin, Daniela Toneatto

Open Forum Infect Dis· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.
Jiří Beran, Daniel Dražan, Igwebuike Enweonye, Chiranjiwi Bhusal, Daniela Toneatto

mSphere· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents.
Timo Vesikari, Jerzy Brzostek, Anitta Ahonen, Marita Paassilta, Ewa Majda-Stanislawska, Daniela Toneatto

Hum Vaccin Immunother· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adults.
Federico Martinón-Torres, Terry Nolan, Daniela Toneatto, Angelika Banzhoff

Hum Vaccin Immunother· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does vaccination with 4CMenB convey protection against meningococcal serogroup B strains not predicted to be covered by MATS? A study of the UK clonal complex cc269.
Maria Stella, Maria Giuliani, Alessia Biolchi, Sara Tomei, Rosita De Paola, Daniela Toneatto

Hum Vaccin Immunother· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of strain coverage of the multicomponent meningococcal serogroup B vaccine (4CMenB) administered in infants according to different immunisation schedules.
Alessia Biolchi, Sara Tomei, Laura Santini, Jo Anne Welsch, Daniela Toneatto

Hum Vaccin Immunother· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) administered concomitantly with the meningococcal serogroup B (4CMenB) vaccine in infants: A post-hoc analysis in a phase 3b, randomised, controlled trial.
Marco Aurelio P Safadi, Federico Martinon-Torres, Lily Yin Weckx, Edson Duarte Moreira, Eduardo Jorge da Fonseca Lima, Daniela Toneatto

Vaccine· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine.
Terry Nolan, Maria Elena Santolaya, Ferdinandus de Looze, Helen Marshall, Peter Richmond, Daniela Toneatto

Vaccine· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
Mercedes Macias Parra, Angela Gentile, Jorge Alejandro Vazquez Narvaez, Alejandro Capdevila, Angel Minguez, Daniela Toneatto

Vaccine· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function.
Federico Martinón-Torres, Ewa Bernatowska, Anna Shcherbina, Susanna Esposito, Leszek Szenborn, Daniela Toneatto

Pediatrics· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study.
Jo Anne Welsch, Shelly Senders, Brandon Essink, Thomas Klein, Igor Smolenov, Daniela Toneatto

Vaccine· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.
Leszek Szenborn, Stan L Block, Teresa Jackowska, Ryszard Konior, Diego D'Agostino, Daniela Toneatto

Pediatr Infect Dis J· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a meningococcal B recombinant vaccine when administered with routine vaccines to healthy infants in Taiwan: A phase 3, open-label, randomized study.
Nan-Chang Chiu, Li-Min Huang, Arnold Willemsen, Chiranjiwi Bhusal, Ashwani Kumar Arora, Daniela Toneatto

Hum Vaccin Immunother· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Four-year antibody persistence and response to a booster dose of a pentavalent MenABCWY vaccine administered to healthy adolescents and young adults.
Xavier Sáez-Llorens, Johnny Beltran-Rodriguez, Jose M Novoa Pizarro, Ilhem Mensi, Pavitra Keshavan, Daniela Toneatto

Hum Vaccin Immunother· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody persistence and booster responses 24-36 months after different 4CMenB vaccination schedules in infants and children: A randomised trial.
Federico Martinón-Torres, Alfonso Carmona Martinez, Róbert Simkó, Pilar Infante Marquez, Josep-Lluis Arimany, Daniela Toneatto

J Infect· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules.
Manish Sadarangani, Tim Sell, Mildred A Iro, Matthew D Snape, Merryn Voysey, Daniela Toneatto

CMAJ· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial.
Federico Martinón-Torres, Marco Aurelio P Safadi, Alfonso Carmona Martinez, Pilar Infante Marquez, Juan Carlos Tejedor Torres, Daniela Toneatto

Vaccine· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging experience with meningococcal serogroup B protein vaccines.
Daniela Toneatto, Mariagrazia Pizza, Vega Masignani, Rino Rappuoli

Expert Rev Vaccines· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].
Mildred A Iro, Matthew D Snape, Merryn Voysey, Sena Jawad, Adam Finn, Daniela Toneatto

Vaccine· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial.
Marco Aurelio P Safadi, Federico Martinon-Torres, Lily Yin Weckx, Edson Duarte Moreira, Eduardo Jorge da Fonseca Lima, Daniela Toneatto

Vaccine· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial.
Mildred A Iro, Matthew D Snape, Merryn Voysey, Sena Jawad, Adam Finn, Daniela Toneatto

Vaccine· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis